Simultaneous Estimation of Pregabalin and Methylcobalamine in Pharmaceutical Formulation by RP-HPLC Method
Bhatt KK, Emanual Michael Patelia* and Aswin Mori
Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipcowala College of Pharmacy, Gujarat, India
- *Corresponding Author:
- Emanual Michael Patelia
Department of Pharmaceutical Chemistry and Analysis
Indukaka Ipcowala College of Pharmacy
New Vallabh Vidyanagar–388121, Gujarat, India
E-mail: [email protected]
Received date: January 15, 2013; Accepted date: January 28, 2013; Published date: January 31, 2013
Citation: Bhatt KK, Patelia EM, Mori A (2013) Simultaneous Estimation of Pregabalin and Methylcobalamine in Pharmaceutical Formulation by RP-HPLC Method. J Anal Bioanal Tech 4:159. doi: 10.4172/2155-9872.1000159
Copyright: © 2013 Bhatt KK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A simple, precise, rapid, selective, and economic reversed phase high-performance liquid chromatography (RPHPLC) method has been established for simultaneous analysis of PRG and MC. A Phenomenex C18 (250×4.6 mm i.d) chromatographic column equilibrated with mobile phase water: methanol (60:40 v/v) adjusted to pH 6.5 with Triethylamine (1% v/v) was used. Mobile phase flow rate was maintained at 1 ml/min and effluents were monitored at 218 nm. The sample was injected using a 20 μl fixed loop, and the total run time was 10 min. Experimental conditions such as pH of mobile phase, column saturation time, selection of wavelength, etc. were critically studied and the optimum conditions were selected. The calibration curve 50-300 μg/ml for PRG and 0.5-2.0 μg/ml for MC. The limit of quantification was 24.10 μg/ml for PRG and 0.40 μg/ml for MC respectively. This HPLC procedure is economic, sensitive, and less time consuming than other chromatographic procedures. It is an importance tool for analysis of combined dosage form.